At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Lyral®biological
Likely dose
Lyral® 0.10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study
In Brief
A Phase 2 clinical trial evaluating Lyral® for Contact Dermatitis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine optimal allergen dose as the lowest concentration eliciting positive reactions in 70-90% of subjects. Frequency of positive, negative, doubtful and irritant reactions, and concordance with a corresponding reference allergens will be captured.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContact Dermatitis
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
Primary CompletionJun 2013
First PostedJan 2014
TodayJul 2026
First PostedJan 7, 2014
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.5 years ago
Interventions
Lyral®biological
Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control